BioVie can sell up to $6,464,341 ($6.46 million) of Class A common stock through A.G.P. under an at-the-market agreement, with proceeds intended for general corporate purposes. Investors face potential dilution, while the final amount raised, commissions and net proceeds remain dependent on sales because the offering has no minimum requirement.

Key Highlights

  • BioVie may sell up to $6,464,341 of Class A common stock through A.G.
  • The offering has no minimum amount required as a condition to close.
  • BioVie intends to use any net proceeds for general corporate purposes.

BIOVIE INC. (NASDAQ: BIVI) can sell up to $6,464,341 ($6.46 million) of Class A common stock through A.G.P. Under an at-the-market sales agreement.

A.G.P. To Handle At-the-Market Sales

A.G.P. May act as BioVie’s sales agent or principal for transactions conducted from time to time. The shares carry a Par Value of $0.0001 per share, and the last reported sales price on September 8 was $2.07 per share. It excludes 2,785,363 shares issuable through options, 7,293,498 shares issuable through warrants and 300 shares tied to restricted stock units.

Dilution Disclosure

The filing reports an as-adjusted net tangible Book Value of $11.4 million, or $1.34 per share. The prospectus says a purchaser’s interest may be diluted by the difference between the public offering price and the adjusted net tangible book value per share.